🇺🇸 FDA

Company profile · Sponsor

Serono

Serono Europe Limited

E48789C · EMA pharma GB
Pipeline
8
Drugs
0
Patents
0

Quick answer

Serono (E48789C) is a pharma company. headquartered in GB. listed on EMA. NovaPharmaNews links 8 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker E48789C
Exchange EMA
Company type pharma
Headquarters GB

Pipeline (8)

Search pipeline →

  1. Avelumab

    Serono

    First Line Non-Small Cell Lung Cancer

    phase 3 small molecule completed

    1 trial

  2. Xevinapant (Debio 1143)

    Serono

    Squamous Cell Carcinoma of the Head and Neck

    phase 3 small molecule terminated

    1 trial

  3. Atacicept 75 mg

    Serono

    Lupus Erythematosus, Systemic

    phase 2 small molecule terminated

    1 trial

  4. Enpatoran low dose

    Serono

    Systemic Lupus Erythematosus

    phase 2 small molecule completed

    1 trial

  5. M5049

    Serono

    Coronavirus Disease 2019

    phase 2 small molecule completed

    1 trial

  6. M9140

    Serono

    Solid Tumors

    phase 2 small molecule active

    1 trial

  7. Placebo

    Serono

    Systemic Lupus Erythematosus

    phase 2 small molecule terminated

    1 trial

  8. Tepotinib

    Serono

    Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is Serono?

Serono (E48789C) is a pharma company. headquartered in GB. listed on EMA. NovaPharmaNews links 8 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does Serono sponsor?

We track 8 ClinicalTrials.gov-linked programs for Serono, including Avelumab and 7 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Serono company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.